Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

被引：0
|
作者：
Ottmann, Oliver G. [1 ]
DeAngelo, Daniel J. [2 ]
Garcia-Manero, Guillermo [3 ]
Luebbert, Michael [4 ]
Jillella, Anand [5 ]
Sekeres, Mikkael A. [6 ]
Zahlten, Anita [7 ]
Squier, Margaret [8 ]
Acharyya, Suddhasatta [8 ]
Winiger, Ivo J. [7 ]
Fenaux, Pierre [9 ]
机构：
[1] Goethe Univ Frankfurt, Dept Internal Med, Frankfurt, Germany
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Freiburg, D-79106 Freiburg, Germany
[5] Georgia Hlth Sci Univ, Augusta, GA USA
[6] Cleveland Clin, Cleveland, OH 44106 USA
[7] Novartis Pharma AG, Basel, Switzerland
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Hop Avicenne, AP HP, F-93009 Bobigny, France
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：212 / 213
页数：2
相关论文
共 50 条
  • [31] PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia
    Bataller, Alex
    Chien, Kelly S.
    Sasaki, Koji
    Montalban-Bravo, Guillermo
    Kanagal-Shamanna, Rashmi
    Urrutia, Samuel
    Almanza-Huante, Emmanuel
    Gener-Ricos, Georgina
    Ravandi, Farhad
    Jabbour, Elias
    Kadia, Tapan
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    LEUKEMIA RESEARCH, 2023, 127
  • [32] Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study
    Madry, Krzysztof
    Lis, Karol
    Biecek, Przemyslaw
    Mlynarczyk, Magda
    Rytel, Agoda
    Gorka, Michal
    KacFrzyk, Piotr
    Dutka, Magdalena
    Rodzaj, Marek
    Bolkun, Lukasz
    Krochmalczyk, Dorota
    Latka, Ewa
    Drozd-Sokolowska, Joanna
    Waszczuk-Gajda, Anna
    Knopinska-Posluszny, Wanda
    Kopinska, Anna
    Subocz, Edyta
    Masternak, Anna
    Guzicka-Kazimierczak, Renata
    Gil, Lidia
    Machowicz, Rafal
    Bilinski, Jaroslaw
    Giebe, Sebastian
    Czerw, Tomasz
    Dwilewicz-Trojaczek, Jadwiga
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (05): : 264 - +
  • [33] A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    DiNardo, Courtney D.
    Olin, Rebecca
    Ishizawa, Jo
    Sumi, Hiroyuki
    Xie, Jingdong
    Kato, Kazunobu
    Kumar, Prasanna
    Andreeff, Michael
    BLOOD, 2019, 134
  • [34] A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)
    Navada, S. C.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Alvarado, Y.
    Daver, N.
    DiNardo, C.
    Konopleva, M.
    Borthakur, G.
    Azarnia, N.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2015, 39 : S45 - S45
  • [35] Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia-a wise Liaison?
    Platzbecker, U.
    Germing, U.
    LEUKEMIA, 2013, 27 (09) : 1813 - 1819
  • [36] A Phase I/II Study of Seclidemstat, an LSD1 Inhibitor, and Azacitidine for Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
    Montalban-Bravo, Guillermo
    DiNardo, Courtney D.
    Short, Nicholas
    Kadia, Tapan M.
    Ravandi, Farhad
    Chien, Kelly S.
    Joseph, Joby
    Waukau, Jane
    Pierce, Sherry A.
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2022, 140 : 9771 - 9772
  • [37] Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia
    Weihrauch, MR
    Staib, P
    Seiberlich, B
    Hoffmann, M
    Diehl, V
    Tesch, H
    LEUKEMIA & LYMPHOMA, 2004, 45 (04) : 699 - 704
  • [38] IMPACT OF AZACITIDINE TREATMENT ON INFECTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA, MYELODYSPLASTIC SYNDROMES AND MYELODYSPLASTIC/MYELOPROLIFERATIVE SYNDROMES
    Villegas, C.
    Ortiz, S.
    Javier, K.
    Costa, S.
    Ivars, D.
    Collado, R.
    Lopez, M.
    Irene, L.
    Roig, M.
    Sanchez, M.
    Perez, P.
    Orero, M.
    HAEMATOLOGICA, 2016, 101 : 483 - 483
  • [39] The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
    Chien, Kelly S.
    Kanagal-Shamanna, Rashmi
    Naqvi, Kiran
    Sasaki, Koji
    Alvarado, Yesid
    Takahashi, Koichi
    Kadia, Tapan M.
    Borthakur, Gautam M.
    Jabbour, Elias
    Routbort, Mark
    Pierce, Sherry A.
    Soltysiak, Kelly
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    BLOOD, 2019, 134
  • [40] Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study
    Tan, Peter T.
    Reed, Kate
    Walker, Patricia A.
    Avery, Sharon
    Patil, Sushrut S.
    Grigg, Andrew
    Mollee, Peter
    Gervasio, Othon L.
    Winiger, Ivo J.
    Hoenemann, Dirk
    Wei, Andrew H.
    Spencer, Andrew
    BLOOD, 2011, 118 (21) : 664 - 664
12345